The global scaffold technology market size was estimated to be worth USD 727.7 million in 2018 and is anticipated to grow at a CAGR of 10.38% from 2019 to 2026. Scaffold technology is a 3D presentation of tissue culture. It is a branch of Tissue Engineering (TE) that performs 3D cultural assays, overcoming limitations imposed upon by 2D Cell culture for various drug delivery and development process. 3D cultural assays comprise cell to cell interactions, cell to matrix interactions and cell migration assays. Scaffold technology mimics new cells from the body to engage new tissues that will replicate damaged tissues from highly porous scaffold biomaterials. Thus, new tissues are generated on lines of scaffold biomaterials acting as a template to growth. Scaffold technology works on principle of cell biology maintaining 3D cell architecture on the go.
Scaffold Technology seeks a persistent evolution of technology with dependence on cellular biology that brings to the fore biological substitutes for regenerative action by taking on diseased organs or tissues. This technology also brings to the fore in vivo and in vitro tissue regeneration within synthetic polymeric scaffolds.
Know more about this report: request for sample pages
The drivers to growth of scaffold technology market are an unrelenting investment in R&D, a driving need for organ transplantation, gigantic strides in tissue engineering and a premise to replace unhealthy organs or tissues. An increasing pattern sought after in stem cell research in cancer, attributes success to 3D cell culture modeling. This could step-up market growth invaluably.
An exciting format whereby it is practically feasible to transplant the new organs in place of damaged organs, at the desired place is proving to be a unique feat for the industry, fulfilling growth. Scaffold technology rests on the back of tissue engineering with regenerative medicine. Scaffolds are either implanted in vitro or in vivo. While transplanting tissues as a replacement for injured tissues, key considerations such as biocompatibility, mechanical properties, biodegradability and scaffold architecture have to be surmised.
The major factor driving this technology is increasing R&D efforts that are taken with real time biological translation meaning developing biological substitutes for replacement and regenerating the deceased organs or tissues. Additionally, 3D cell adoption is one up on 2D cell culture with various drug development and discovery process happening with 3D model thus influencing growth of the market. Key companies are developing innovative stem cell substrates and helping out with regenerative medicines and organogenesis modeling supporting growth. Some drawbacks associated with 3D cell culture are limiting growth during forecast period.
By End Use
Know more about this report: request for sample pages
The global scaffold technology market is segmented on the basis of product, application, use and geography. Based on Product type, scaffold technology is segmented as polymeric, hydrogels, micropatterned surface microplates, freeze embryo testing and Nano fiber-based scaffolds.
Hydrogels accumulated maximum share in global scaffold technology because of ease of regulated drug delivery is possible and biocompatibility of hydrogel with host tissue is on the cards. The hydrogels have a lot going for them by way of similarity with native tissues and furthermore its insolubility in water traits that stimulate additional growth for the market.
Based on application, scaffold technology is divided into drug development, stem cell research, cancer, tissue engineering and clinical application and others. Cancer application accounts for maximum growth in market obviously for large number of human population being susceptible to various types of cancer. Additionally, the infallibility of 3D cell culture in cancer research and stem cell development in collaboration with scaffold technology drives maximum growth for cancer application segment.
On the basis of end-use, scaffold technology is segmented into research laboratories and institutes, biotechnologies and pharmaceutical organizations hospitals and diagnostic centers and others. Biotechnology and Pharmaceutical organizations accounted for maximum market share because of on-going research and development by the manufacturers. Large investments in this area of research have also contributed to growth for biotechnology and pharmaceutical organizations. Online pharmacy segment is also slated to grow at a feverish pace during forecast period because of penetration of internet in developing countries and a new order of purchasing medicines online. This trend has caught early on in India where medicines are brought online though Government regulations deny this right with a strict regulatory framework in place.
By regions, scaffold technology market is segmented into North America, Europe, Asia Pacific, Latin America and MEA. Geographically, North America dominates the market owing to large number of cases of cancer registered here and increasing death toll due to cancer. According to WHO, cancer comes second as the leading cause of death globally accounting for nearly 9.6 million deaths in 2018 and influencing market growth. Increase in funding by Government and regional players supports market growth with constant R&D efforts underway helps growth of this technology. Growth in Asia pacific is also expected to go on unheeded because of increasing investments in healthcare by Government and controlled use of this technology. Adding to it is surging number of patients suffering from cancer and underscoring awareness of use of organ transplant. Rising smoking habits and alcohol abuse in the region also drives market in Asia Pacific.
Key players operating in market include Merck and Company, Thermo Fischer Scientific Inc., 3D Biotek LLC, Pelo Biotek GmbH, Corning, Inc., and Becton Dickinson and Company, Avacta Life Sciences Limited, Nanofiber Solutions, NuVasive, Inc., ReproCELL Europe Ltd., MArticell GmbH, Teca n Trading AG and Molecular Matrix Inc.